• Supports addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• Requires Designated Mentor who is an independent, established kidney cancer investigator with a record of kidney cancer publications in peer-reviewed journals.
• Designated Mentor not required to be at the same institution as the ECI.
• Preliminary data required.
• Funding for clinical trials not allowed.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact in the field of kidney cancer.
• Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.
• Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place by the time of application submission.
• Letter of support demonstrating proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).
• Clinical trials are expected to be initiated within 12 months of the award date.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $2,000,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• Prepares nurses for active careers in collaborative clinical kidney cancer research and patient care.
• Requires participation of a mentor with extensive experience in kidney cancer clinical research.
• Emphasis placed on structured, interdisciplinary clinical research training environment.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $300,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.

• Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.
• Emphasis on innovation.
• Funding for clinical trials not allowed.
• Preliminary data not allowed.
• Blinded review.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $75,000 for direct costs (plus indirect costs).
• Maximum period of performance is 1 year.

Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency/fellowship or family medical leave) at the time of application submission deadline.

• Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
• Preliminary data required.
• Innovation and Impact are the most important review criteria.
• Funding for clinical trials not allowed.
• Different funding options, based on the scope of research. It is the responsibility of the PI to select the funding option that is most appropriate for the research proposed. 
• Early Detection Studies Option: Supports basic or preclinical research that focuses on biomarkers, improved imaging capabilities, and/or new technologies that may foster new paradigms for the early detection of kidney cancer. With justification, applications under the early detection studies option may request a higher level of funding within the defined period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
• Population Science and Prevention Studies Option: Supports preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the kidney cancer field. With compelling justification, population science and prevention studies option studies may request higher levels of funding within the defined period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
• Pre-application is required; application submission is by invitation only.

• Maximum funding of $600,000 in direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

Early Detection Option:

• Maximum funding of $650,000 in direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

Population Science and Prevention Studies Option:

• Maximum funding of $2 million in direct costs (plus indirect costs).
• Maximum period of performance is 4 years.

• Must possess a doctoral and/or medical degree (or equivalent).
• Have 3 years or less of postdoctoral and/or mentored clinical research training experience (excluding family medical leave).
• All other academic ranks are ineligible.

• Supports research opportunities focused on kidney cancer for individual in the early stages of their careers.
• Requires participation of a designated mentor who is an experienced kidney cancer researcher.
• Submission of a Letter of Intent required prior to full application submission.

• Maximum funding of $195,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

• Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
• Supports translational correlative studies.
• Preliminary data required.
• Funding for clinical trials not allowed.
• Pre-application is required; application submission is by invitation only.

• Maximum funding of $750,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.